New Delhi: In a big move, Bharat Biotech’s Covaxin has reportedly received approval from Subject Expert Committee (SEC) on COVID-19 for emergency use in children above 2 years in India.
The SEC has submitted recommendations to Drugs Controller General of India (DCGI) for approval of the vaccine for use on children, stated reports.
Once approved, Covaxin will become only second vaccine cleared for use on kids and the only such vaccine for toddlers too. In August, Zydus Cadilla’s three-dose DNA jab was allowed to be used on adults and children over 12.
The Hyderabad-based company had completed Phase-2 and Phase-3 trials of Covaxin on children below 18 years of age in September.
A third potential vaccine for kids is Serum Institute’s Novavax, for which the DCGI last month cleared trials for children between seven and 11 years.
Mumbai: Television actor Nitin Chauhan’s untimely demise at the age of 35 has once again…
Cuttack: Vendors will not be allowed to do business on footpaths during the upcoming Bali…
Mumbai: Sandeep Pattanaik completed a fighting century but that didn’t help Odisha avoid a follow-on…
Bhubaneswar: After several Biju Janata Dal (BJD) leaders blamed VK Pandian for the regional party’s…
Mumbai: The Congress-National Conference (NC) alliance which formed the government in Jammu & Kashmir after winning…
New Delhi: It was the last day in office for Dhananjaya Yeshwant Chandrachud as Chief…
Cuttack: The Orissa High Court has refused to quash a criminal case against a lawyer…
Bhubaneswar: The cyclonic circulation over southwest Bay of Bengal is likely to intensify into a…